Rise and shine, everyone. The middle of the week is upon us. Have heart, though. You made it this far, so why not hang on for another couple of days, yes? And what better way to make the time fly than to keep busy. So grab that cup of stimulation and get cracking. For those who track this sort of behavior, we are brewing, once again, the oh-so-seasonal pumpkin spice. Meanwhile, do keep us in mind if you hear anything interesting. Have a smashing day …

The number of new clinical trials started in the U.K. last year was 25 percent lower than the average for 2009-16, as anxiety about the Brexit impact on future medicines regulation made companies hesitate about running studies in the country, Reuters explains. A total of 597 trials were initiated in the U.K. in 2017, against an average of 806 over the previous eight years. The pharmaceuticals industry has long warned that Brexit could have a serious impact on research and access to medicines, unless London and Brussels reach a deal for regulatory continuity.

Unlock this article by subscribing to STAT Plus and enjoy your first 30 days free!


What is it?

STAT Plus is STAT's premium subscription service for in-depth biotech, pharma, policy, and life science coverage and analysis. Our award-winning team covers news on Wall Street, policy developments in Washington, early science breakthroughs and clinical trial results, and health care disruption in Silicon Valley and beyond.

What's included?

  • Daily reporting and analysis
  • The most comprehensive industry coverage from a powerhouse team of reporters
  • Subscriber-only newsletters
  • Daily newsletters to brief you on the most important industry news of the day
  • Online intelligence briefings
  • Frequent opportunities to engage with veteran beat reporters and industry experts
  • Exclusive industry events
  • Premium access to subscriber-only networking events around the country
  • The best reporters in the industry
  • The most trusted and well-connected newsroom in the health care industry
  • And much more
  • Exclusive interviews with industry leaders, profiles, and premium tools, like our CRISPR Trackr.

A roundup of STAT’s top stories of the day in science and medicine

Privacy Policy